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The RIFLE classification was introduced in 2004 to describe the presence of acute kidney injury (AKI) and to define
its clinical stage, based upon the serum creatinine level and urine output. The same criteria, although slightly
modified, are used in the other scoring systems AKIN and KDIGO. Mortality and morbidity remain high in AKI,
suggesting that current diagnostic methods are suboptimal, poorly accurate, and often timely inadequate in
detecting the presence of early kidney injury. Conversely, a growing body of evidence indicates that new AKI
biomarkers can be used to both rule out AKI and to assess high-risk conditions or the presence of subclinical
forms. Neutrophil gelatinase-associated lipocalin or cell cycle arrest biomarkers seem to be sensitive and specific
enough to be used in conjunction with existing markers of AKI for better classifying renal injury as well as dysfunction.
Improvements in diagnosis, risk identification, stratification, prognosis, and therapeutic monitoring may improve
prevention and protection from organ damage and help to identify patients at risk, allowing individualized therapy. In
this view, we may say that AKI diagnosis has finally moved from clinical to molecular level with potential benefits for
the patients because similar progress has been shown in other disciplines.
The incidence of acute kidney injury (AKI) is increasing
especially in hospitalized patients and particularly in the
ICU due to major surgery, iatrogenic interventions, and
sepsis. In such conditions, age and comorbidities make
the kidneys more susceptible to various exposures and
insults [1]. Diagnostic criteria based on oliguria and
serum creatinine (SCr) seem inadequate to describe the
wide spectrum of mechanisms and conditions of AKI
(Fig. 1). The RIFLE, AKIN, and KDIGO classifications
have made some important advancements [2–4] but
they still rely only on urine output and SCr, precluding
the possibility of a timely and accurate AKI diagnosis,
and neglecting subclinical forms of kidney dysfunction
and damage.
New biomarkers can detect a risk of AKI or subclinical
kidney damage earlier, allowing development of a new
conceptual model for AKI with a continuum from initial
kidney stress and early injury to advanced kidney dam-
age and/or failure. The acute phase has also been called
“Kidney Attack” [5] while the subsequent phases in the
time window of 90 days are described as acute kidney
disease (AKD). Full recovery or maladaptive repair with
progression towards chronic kidney disease (CKD) is
also a pathway described in the model. At each point of
the continuum, biomarkers may play a role in clarifying
mechanisms and clinical evolution of AKI. Studies on
biomarkers have described their positive and negative
predicting value for the presence and severity of the
syndrome, site of damage, need for renal replacement
therapy (RRT), and recovery or progression towards
CKD [6]. Unfortunately, these studies present a high
degree of heterogeneity, and meaningful conclusions
are only obtained in specific populations.
Zhang et al. [7] conducted a meta-analysis focusing
on the value of neutrophil gelatinase-associated lipoca-
lin (NGAL) to predict AKI and clinical outcomes such
as need for RRT and mortality in a specific subset of
patients with sepsis. Fifteen studies were included in
the analysis, confirming high-pooled sensitivity and
specificity values for both plasma and urine NGAL. The
authors concluded that NGAL is not only a good pre-
dictor of AKI but is also an efficient test to predict the
need for RRT and mortality in septic patients.
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Some questions remain open. Do we have discrete quan-
titative values correlated with level of damage/dysfunction
or outcome? Can we diagnose AKI only in the basis of
these molecular markers even in the absence of abnormal
urine output or SCr? Does the cost/benefit ratio justify the
use of these expensive biomarkers in critically ill patients?
Are we ready to use these biomarkers routinely?
Not only can biomarkers be used to establish the pres-
ence and the severity of AKI, but they may also be used to
identify a status of kidney stress or an increased susceptibil-
ity to insults. In such conditions, they may trigger early pre-
ventive and protective measures well before clinical AKI
becomes manifest according to the KDIGO criteria [8].
The ADQI consensus group proposed the use of bio-
markers to diagnose AKI with kidney damage even in
the absence of renal dysfunction [9]. In a recent publica-
tion, de Geus et al. [10] concluded that NGAL is a good
predictive marker for AKI in high-risk cardiac surgery
patients and generated a NGAL score identifying a
meaningful threshold for both plasma and urine NGAL
values. The score contains memorable NGAL levels use-
ful to rule out AKI or to quantify the degree of tubular
damage. In the same line, the recent validation of
discrete limits of cell-cycle arrest biomarkers (TIMP-2
and IGFBP-7) allows one to rule out AKI or to identify
high-risk conditions for AKI. These biomarkers can de-
scribe a condition of kidney stress highly predictive of
mild to severe AKI [11]. Biomarker levels may change
over time, allowing identification of different phases of
the syndrome such as increased susceptibility and risk,
subclinical kidney damage, tissue regeneration, and re-
covery or progression towards CKD. Subclinical AKI
may be diagnosed only with the use of biomarkers,
when classic criteria are still within normal range
(Fig. 2) [12, 13]. Specific biomarkers may represent a
molecular signature for every type of insult (e.g., ische-
mia, sepsis, toxic elements, etc.). Moving from clinical
to molecular diagnosis of AKI may allow characterizing
the causative role of specific pathogenic factors and
may help to develop individual criteria and decision-
making frameworks for the etiological variants of AKI.
AKI biomarkers are useful also to identify conditions of
partial recovery, maladaptive repair, and progression to-
wards CKD, important consequences of AKI also for
health care providers. A cost/benefit ratio may be in-
ferred by the application of biomarkers in specific pop-
ulations. Implementation of routine use of biomarkers
triggering specific alert conditions and rapid response
strategies may help prevent evolution of AKI into more
severe stages or requirement for RRT. If this happens
even in a limited cohort of patients where RRT can be
avoided or progression to CKD can be prevented, the
financial advantage of biomarkers will become evident
for patients and even for health care providers.
In conclusion, some of the key questions about bio-
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Fig. 1 Evolution of AKI diagnostic syntax. The discovery and validation of cell cycle arrest biomarkers, neutrophil gelatinase-associated lipocalin,
and other markers have permitted introduction of the concepts of AKI risk, kidney stress, and subclinical AKI. Quantitative evaluation of these
markers has moved the diagnosis of AKI from the clinical/biochemical level to the cellular/molecular level. AKI acute kidney injury, AKIN Acute
Kidney Injury Network, KDIGO Kidney Disease Global Outcome Initiative, RIFLE Risk, Injury, Failure, Loss and End Stage Kidney Disease, ATN
Acute Tubular Necrosis, ARF Acute Renal Failure
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additional value of making an early and accurate diag-
nosis of AKI is gaining evidence and the role of bio-
markers is increasing. Discrete quantitative values
correlating with the level of damage/dysfunction are
available and they will foster further studies of valid-
ation and support. Beyond the detection of increased
risk and kidney stress conditions, today we can make a
diagnosis of AKI based solely on molecular criteria
even in the presence of normal urine output or SCr.
The concept is mirroring what happened in the acute
coronary syndrome in the absence of ST elevation on
the EKG, where troponin made possible the diagnosis
of non-ST elevation myocardial infarction. [15]. All of
these considerations may suggest a remarkable cost/
benefit advantage justifying the use of expensive bio-
markers in specific populations. Thus, we will prob-
ably soon be ready to use AKI biomarkers routinely
for the benefit of the patients and the strategic evolu-
tion of our healthcare plans.
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